# Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT01699152** · PHASE1 · COMPLETED · sponsor: **Tragara Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** TG02 citrate

## Key facts

- **NCT ID:** NCT01699152
- **Lead sponsor:** Tragara Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-07
- **Final completion:** 2016-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01699152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01699152, "Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01699152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*